← Return to all swing-trade opportunities
TEVA — Trend Pullback to 20 EMA
Status: Watch
Scanner score: 75.0/100
Why this was flagged
TEVA was identified as a bullish technical setup based on the Trend Pullback to 20 EMA pattern. The scanner found a score of 75.0/100 using trend alignment, momentum, price action, volume, and risk-management rules.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
The computer program looked at Teva Pharmaceutical Industries and gave it a score of 75 out of 100. This happened because the stock fits a pattern called a Trend Pullback to the 20 EMA. In simple terms, the stock usually moves up, but it took a short break to come back down. This is like a runner taking a drink of water before running fast again. The program noticed that the price is currently sitting near this important line, called the 20-day moving average, which shows the average price for the last month. It also saw that the longer-term trends look positive.
What the price plan means
Traders who like this idea plan to look at prices between $37.10 and $37.37. If they decide to follow along, they would set a safety net at $35.49. This safety net protects them if the stock goes down. They also have two goal prices, or targets, at $40.32 and $41.93. The plan offers a reward that is twice as big as the risk. For every dollar they might lose, they aim to gain two dollars. The Relative Strength Index, or RSI, is at 48. This shows the stock is not moving too fast in either direction.
What could make the idea fail
The signal is valid until September 21, 2026. After that date, the plan stops working. Also, the volume is lower than usual right now, which means fewer people are trading the stock. Sometimes, trends do not continue. If the price falls below the $35.49 safety line, the idea is no longer valid, and traders would follow their stop-loss rule to exit.
Important reminder
This text explains what the scanner found. It is not financial advice. Always check your own facts and talk to a professional before making choices with your money.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Positive (Moderate confidence)
Teva Pharmaceutical Industries has seen positive analyst sentiment recently, with Leerink Partners initiating coverage with an 'outperform' rating and UBS raising its price target to $48.00. The company received an upgrade to investment-grade status from S&P Global Ratings, and institutional investors have increased their stakes in the stock. Additionally, Teva reported successful Phase 2A trial results for its experimental celiac disease drug, TEV-408, which the company projects could generate $1.5 billion to $2 billion in annual sales. However, the stock faces risks from recent insider selling, with an executive selling over 106,000 shares, and geopolitical concerns after a Russian attack on a Teva warehouse in Ukraine, raising potential supply chain disruptions.
Potentially supportive context
- Leerink Partners initiated coverage with an 'outperform' rating and $45 price target, while UBS raised its target to $48.00.
- Teva's experimental celiac disease drug, TEV-408, met its main goal in a Phase 2A trial and is projected to generate $1.5 billion to $2 billion in annual sales.
- The company received an upgrade to investment-grade status from S&P Global Ratings, and institutional investors have increased their stakes in Teva's stock.
Risks and caution items
- An executive sold over 106,000 shares, indicating recent insider selling activity.
- A Russian attack on a Teva warehouse in Ukraine has raised concerns about potential disruptions to the company's medicine supply chain.
- Teva is transitioning its NYSE listing by ending its ADS program, which may introduce operational or market transition risks for some investors.
- One analyst recently downgraded Teva's stock to a 'hold' rating, reflecting mixed opinions among analysts.
Latest reviewed article: Sep 9, 2026 2:27 pm
Recent related articles
Leerink Partners has initiated coverage on Teva Pharmaceutical Industries (NYSE:TEVA) with an "outperform" rating and a $45 price target, suggesting a 21.51% upside. This positive outlook aligns with a "Moderate Buy" consensus from other analysts, with an average target price of $43.10.…
Leerink Partners has initiated coverage on Teva Pharmaceutical Industries with an Outperform rating and set a $45 price target. This announcement comes amid other recent news for Teva, including an S&P Global Ratings upgrade and positive topline results from a Phase 2A…
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD has acquired a significant position in Teva Pharmaceutical Industries Ltd. ($TEVA), purchasing nearly one million shares valued at $33.8 million, making it their fourth-largest holding. This move highlights continued institutional interest in Teva, with…
Compass Financial Management LLC has acquired a new stake of 32,254 shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the second quarter, valued at approximately $1.09 million. Institutional investors now own 54.05% of the company's stock. Teva has received positive analyst ratings,…
Nykredit A/S has acquired a new stake of 443,442 shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), valued at approximately $15 million, as disclosed in its latest SEC filing. Institutional investors now own 54.05% of Teva's stock, and analysts maintain a "Moderate Buy"…
UBS Group has increased its price target for Teva Pharmaceutical Industries (NYSE:TEVA) to $48.00 from $42.00, maintaining a "buy" rating and suggesting a potential upside of over 31%. This adjustment follows similar price target increases from other firms, while one analyst downgraded…
Teva Ukraine's warehouse was struck twice by a Russian attack, damaging infrastructure vital for the country's medicine supply chain. While no employees were injured, the pharmaceutical company is assessing the damage and working to prevent disruptions to medication availability for Ukrainian patients.…
Teva Pharmaceutical has amended its deposit agreement to facilitate the listing of its ordinary shares on the NYSE, ending its ADS program on September 14, 2026. This transition will convert outstanding ADSs into NYSE-listed ordinary shares, providing investors with direct equity ownership.…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- Price is above the 20-, 50-, and 200-day moving averages, with bullish moving-average alignment.
- RSI is in a constructive momentum range without being overbought.
- Price is near the 20 EMA in a bullish trend and the current candle is positive.
- Bullish engulfing candle detected.